

# Efficacy of Platelet-rich Plasma for Low Back Pain: A Systematic Review and Meta-analysis

Zhaopeng Xuan<sup>1</sup> Wenjun Yu<sup>1</sup> Yichen Dou<sup>1</sup> Tao Wang<sup>1</sup>

<sup>1</sup>Department of Hand Surgery, The First Hospital of Jilin University, Changchun, Jilin, China

Address for correspondence Tao Wang, MD, Department of Hand Surgery, The First Hospital of Jilin University, No. 218 Ziqiang Street, Nanguan District, Changchun, Jilin, P. R. China 130041 (e-mail: w-t585@163.com).

J Neurol Surg A 2020;81:529–534.

## Abstract

**Background** Platelet-rich plasma (PRP) may be beneficial for patients with low back pain. However, the results remain controversial. We conducted a systematic review and meta-analysis to explore the efficacy of PRP for low back pain.

**Methods** PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases were searched systematically. Randomized controlled trials (RCTs) assessing the effect of PRP on low back pain were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcome was pain scores within 8 weeks. Meta-analysis was performed using the random-effects model.

**Results** Three RCTs involving 131 patients were included in the meta-analysis. Overall, compared with control intervention for low back pain, PRP injection was found to reduce pain scores significantly (mean difference:  $-1.47$ ; 95% confidence interval [CI],  $-2.12$  to  $-0.81$ ;  $p < 0.0001$ ), improve the number of patients with  $> 50\%$  pain relief at 3 months (risk ratio [RR]: 4.14; 95% CI, 2.22–7.74;  $p < 0.00001$ ), and offer relatively good patient satisfaction (RR: 1.91; 95% CI, 1.04–3.53;  $p = 0.04$ ). No increase in adverse events was reported after PRP injection (RR: 1.92; 95% CI, 0.94–3.91;  $p = 0.07$ ).

**Conclusions** Compared with control intervention for low back pain, PRP injection was found to improve pain relief and patient satisfaction significantly with no increase in adverse events.

## Keywords

- ▶ low back pain
- ▶ platelet-rich plasma
- ▶ pain scores
- ▶ systematic review
- ▶ meta-analysis

## Introduction

Low back pain is a common and devastating problem for patients and physicians, and it results in high morbidity and a great economic burden.<sup>1–5</sup> Low back pain is the most common cause of disability of patients between 45 and 65 years of age.<sup>6,7</sup> Approximately 20% of patients have a recurrence within 6 months of the initial episode, and some experience chronic symptoms. Numerous factors can cause low back pain including intervertebral disk herniation and lumbar facet joint syndrome.<sup>8–11</sup>

Platelet-rich plasma (PRP) is an autologous biological blood-derived product and can release high concentrations of platelet-derived growth factors to enhance the body's natural healing response.<sup>12,13</sup> PRP also possesses antimicro-

bial properties and may have some ability to prevent infections.<sup>14,15</sup> Local injection of PRP is reported to be an effective modality to reduce pain, disability, and functional limitation, and to improve structural integrity and biomechanical strength for various painful conditions including tendinopathy, muscle strain injury, ligament injury, and knee osteoarthritis.<sup>16–21</sup> PRP was found to stimulate the metabolism of intervertebral disk cells in vitro and promote a reparative effect on rabbit degenerated intervertebral disks.<sup>22,23</sup> Intra-articular knee injection of PRP results in pain relief and improves knee function and quality of life in younger patients with a low degree of articular degeneration.<sup>24</sup> Previous studies demonstrated that PRP by periarticular injection, sacroiliac joint injection, or intradiskal injection

received  
May 24, 2019  
accepted after revision  
October 22, 2019  
published online  
May 21, 2020

© 2020 Georg Thieme Verlag KG  
Stuttgart · New York

DOI <https://doi.org/10.1055/s-0040-1709170>  
ISSN 2193-6315.

results in significant improvement in pain scores for low back pain.<sup>25,26</sup>

In contrast to this promising finding, however, some relevant randomized controlled trials (RCTs) showed that PRP injection had no influence on pain scores and patient satisfaction for low back pain.<sup>27,28</sup> Considering these inconsistent effects, we therefore conducted a systematic review and meta-analysis of RCTs to evaluate the effectiveness of PRP injection in patients with low back pain.

## Materials and Methods

This systematic review and meta-analysis were conducted according to the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement<sup>29</sup> and the *Cochrane Handbook for Systematic Reviews of Interventions*.<sup>30</sup> All analyses were based on previous published studies. Thus no ethical approval and patient consent were required.

### Literature Search and Selection Criteria

PubMed, Embase, Web of Science, EBSCO, and the Cochrane Library were systematically searched from inception to September 2017, with the following keywords: *platelet-rich plasma* or *PRP*, and *low back pain* or *lumbar pain*. To include additional eligible studies, the reference lists of retrieved studies and relevant reviews were also hand-searched, and the process was performed repeatedly until no further article was identified. Conference abstracts meeting the inclusion criteria were also included.

The inclusion criteria were as follows: study population, patients with low back pain; intervention, platelet-rich plasma; control intervention; outcome measure, pain scores; and study design, RCT.

### Data Extraction and Outcome Measures

The following information was extracted for the included RCTs: first author, publication year, sample size, baseline characteristics of patients, PRP, control, study design, pain scores within 8 weeks, > 50% pain relief at 3 months, relatively good patient satisfaction, and adverse events. The author was contacted to acquire the data when necessary.

The primary outcome was pain scores within 8 weeks. Secondary outcomes included > 50% pain relief at 3 months, relatively good patient satisfaction, and adverse events.

### Quality Assessment in Individual Studies

The Jadad scale was used to evaluate the methodological quality of each RCT included in this meta-analysis.<sup>31</sup> This scale consisted of three evaluation elements: randomization (0–2 points), blinding (0–2 points), and dropouts and withdrawals (0–1 points). One point would be allocated to each element if they were mentioned in the article, and another 1 point would be given if the methods of randomization and/or blinding were detailed and described appropriately. If methods of randomization and/or blinding were inappropriate, or dropouts and withdrawals had not been recorded, 1 point was deducted. The score of the Jadad scale varies from 0 to 5

points. An article with a Jadad score  $\leq 2$  was considered of low quality. If the Jadad score was  $\geq 3$ , the study was deemed high quality.<sup>32</sup>

### Statistical Analysis


Mean differences (MDs) with 95% confidence intervals (CIs) for continuous outcomes (pain scores within 8 weeks) and risk ratios (RRs) with 95% CIs for dichotomous outcomes (> 50% pain relief at 3 months, relatively good patient satisfaction, and adverse events) were used to estimate the pooled effects. An  $I^2$  value > 50% indicates significant heterogeneity. The random-effects model with DerSimonian and Laird weights was used in all analyses. Sensitivity analysis was performed to detect the influence of a single study on the overall estimate via omitting one study in turn when necessary. Owing to the limited number (< 10) of included studies, publication bias was not assessed. A  $p < 0.05$  in two-tailed tests was considered statistically significant. All statistical analyses were performed with Review Manager v.5.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom).

## Results

### Literature Search, Study Characteristics, and Quality Assessment

The flowchart for the selection process and detailed identification is presented in ► Fig. 1. A total of 372 publications were identified through the initial search of databases. Ultimately, three RCTs were included in the meta-analysis.<sup>25,27,28</sup>

► Table 1 summarizes the baseline characteristics of the three eligible RCTs in the meta-analysis. The three studies were published between 2016 and 2017, and sample sizes ranged from 40 to 46 with a total of 131. The PRP group and control group had similar characteristics at baseline. Two RCTs reported an intra-articular injection with PRP versus a steroid injection,<sup>25,28</sup> and one RCT reported intradiscal PRP versus a contrast agent.<sup>27</sup>



**Fig. 1** Flow diagram of study searching and selection process. RCT, randomized controlled trial.

**Table 1** Characteristics of included studies

No.	Study	PRP group					Control group					Jada scores	
		N	Age, y	Male, n	BMI, kg/m <sup>2</sup>	Methods	N	Age, y	Male, n	BMI, kg/m <sup>2</sup>	Methods		Type
1	Wu et al <sup>28</sup>	23	52.91 ± 7.60	10	22.56 ± 1.39	Intra-articular injection with PRP	23	52.78 ± 7.25	9	22.38 ± 1.45	Intra-articular injection with local anesthetic/corticosteroid	Lumbar facet joint syndrome	5
2	Singla et al <sup>25</sup>	20	35.20 ± 12.86	16	23.69 ± 2.54	Ultrasound-guided sacroiliac joint injection with 3 mL leukocyte-free PRP with 0.5 mL calcium chloride	20	37.00 ± 10.89	16	22.41 ± 2.08	Ultrasound-guided sacroiliac joint injection with 1.5 mL methylprednisolone (40 mg/mL)	Sacroiliac joint pain	3
3	Tuakli-Wosornu et al <sup>27</sup>	29	41.4 ± 8.08	15	-	Intradiscal PRP	16	43.80 ± 8.91	9	-	Intradiscal contrast agent	Symptomatic degenerative intervertebral disk	4

Abbreviations: BMI, body mass index; PRP, platelet-rich plasma.

Among the three RCTs, two studies reported the pain scores within 8 weeks,<sup>25,27</sup> two studies reported > 50% pain relief at 3 months,<sup>25,28</sup> two studies reported relatively good patient satisfaction,<sup>27,28</sup> and three studies reported adverse events.<sup>25,27,28</sup> Jadad scores of the three included studies varied from 3 to 5; all three studies were considered high quality according to our assessment.

### Primary Outcome: Pain Scores within 8 Weeks

These outcome data were analyzed with a random-effects model. The pooled estimate of the two included RCTs suggested that compared with the control group for low back pain, PRP injection was associated with significantly decreased pain scores (MD: -1.47; 95% CI, -2.12 to -0.81;  $p < 0.0001$ ), with no heterogeneity among the studies ( $I^2: 0\%$ ; heterogeneity  $p = 0.84$ ) (►Fig. 2).

### Sensitivity Analysis

No heterogeneity was observed among the included studies for the pain scores. Thus we did not perform a sensitivity analysis by omitting one study in turn to detect the source of heterogeneity.

### Secondary Outcomes

Compared with control intervention for low back pain, PRP injection could substantially improve the number of patients with > 50% pain relief at 3 months (RR: 4.14; 95% CI, 2.22–7.74;  $p < 0.00001$ ; ►Fig. 3) and offer relatively good patient satisfaction (RR: 1.91; 95% CI, 1.04–3.53;  $p = 0.04$ ; ►Fig. 4) with no increase in adverse events (RR: 1.92; 95% CI, 0.94–3.91;  $p = 0.07$ ; ►Fig. 5).

### Discussion

PRP is an autologous blood derivative containing high concentrations of activated growth factors and cytokines (e.g., platelet-derived growth factor, transforming growth factor, fibroblast growth factor, insulinlike growth factor 1, and epidermal growth factor).<sup>33–36</sup> These elements serve as important humoral mediators to induce an anti-inflammatory effect and natural healing cascade by promoting cell proliferation, migration and differentiation, protein transcription, extracellular matrix regeneration, angiogenesis, and collagen synthesis.<sup>37–39</sup>

Our meta-analysis concluded that PRP injection resulted in significantly improved pain relief (as evidenced by the meta-analysis of pain scores within 8 weeks and > 50% pain relief at 3 months) and patient satisfaction for patients with low back pain. In addition, one included RCT revealed that PRP injection was able to result in sustained and more reduction in pain visual analog scores and lumbar functional improvements at the end of 6 months than local anesthetic using a corticosteroid. These results indicated autologous PRP served as the superior treatment option for longer duration efficacy for low back pain compared with corticosteroids. Patients with osteoarthritis of the hip, knee, and ankle experienced significantly favorable pain relief and functional improvement after intra-articular PRP injection.<sup>40–42</sup> A previous study




Fig. 2 Forest plot for the meta-analysis of pain scores within 8 weeks. PRP, platelet-rich plasma.




Fig. 3 Forest plot for the meta-analysis of pain relief at 3 months. PRP, platelet-rich plasma.




Fig. 4 Forest plot for the meta-analysis of relatively good patient satisfaction. PRP, platelet-rich plasma.




Fig. 5 Forest plot for the meta-analysis of adverse events. PRP, platelet-rich plasma.

demonstrated PRP injection produced better clinical outcomes than hyaluronic acid injection at 3 to 12 months posttreatment for knee osteoarthritis.<sup>40</sup>

The complications of PRP injection mainly included complications related to puncture and complications related to various drugs, but they all are exceedingly rare. The adverse events for PRP injection involved postinjection pain and stiffness, chest pain, and difficulty breathing, giddiness, and contralateral pain.<sup>28</sup> Our meta-analysis demonstrated no increase in adverse events after PRP injection compared with control group. All included RCTs reported no serious adverse events.

Several limitations should be considered. First, our analysis was based on only three RCTs, and all of them had a relatively small sample size ( $n < 100$ ). Overestimation of the treatment effect was more likely in smaller trials compared with larger samples. The causes of low back pain in the included studies were different, and it may have had an

influence on the pooling results. Next, the follow-up time of PRP varied from 3 months to 1 year, and longer durations were needed to confirm this issue. Finally, some unpublished and missing data might have led bias to the pooled effect.

### Conclusion

PRP injection showed an important ability to provide pain relief and patient satisfaction for those with low back pain. PRP injection is recommended to be administered for low back pain with caution.

**Conflict of Interest**  
None declared.

### References

1 Dunn KM, Hestbaek L, Cassidy JD. Low back pain across the life course. *Best Pract Res Clin Rheumatol* 2013;27(05):591–600



- 2 Cassidy JD, Côté P, Carroll LJ, Kristman V. Incidence and course of low back pain episodes in the general population. *Spine* 2005;30(24):2817–2823
- 3 Opsommer E, Rivier G, Crombez G, Hilfiker R. The predictive value of subsets of the Örebro Musculoskeletal Pain Screening Questionnaire for return to work in chronic low back pain. *Eur J Phys Rehabil Med* 2017;53(03):359–365
- 4 Paige NM, Miake-Lye IM, Booth MS, et al. Association of spinal manipulative therapy with clinical benefit and harm for acute low back pain: systematic review and meta-analysis. *JAMA* 2017;317(14):1451–1460
- 5 Shiri R. Exercise for the primary prevention of low back pain. *Br J Sports Med* 2017;51(06):551
- 6 Frank JW, Brooker AS, DeMaio SE, et al. Disability resulting from occupational low back pain. Part II: What do we know about secondary prevention? A review of the scientific evidence on prevention after disability begins. *Spine* 1996;21(24):2918–2929
- 7 Suni JH, Taanila H, Mattila VM, et al. Neuromuscular exercise and counseling decrease absenteeism due to low back pain in young conscripts: a randomized, population-based primary prevention study. *Spine* 2013;38(05):375–384
- 8 Burdorf A, Sorock G. Positive and negative evidence of risk factors for back disorders. *Scand J Work Environ Health* 1997;23(04):243–256
- 9 Schwarzer AC, Aprill CN, Derby R, Fortin J, Kine G, Bogduk N. The prevalence and clinical features of internal disc disruption in patients with chronic low back pain. *Spine* 1995;20(17):1878–1883
- 10 Bell JA, Burnett A. Exercise for the primary, secondary and tertiary prevention of low back pain in the workplace: a systematic review. *J Occup Rehabil* 2009;19(01):8–24
- 11 Abdel Shaheed C, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. *JAMA Intern Med* 2016;176(07):958–968
- 12 Wroblewski AP, Mejia HA, Wright VJ. Application of platelet-rich plasma to enhance tissue repair. *Oper Tech Orthop* 2010;20:98–105
- 13 Monfett M, Harrison J, Boachie-Adjei K, Lutz G. Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: an update. *Int Orthop* 2016;40(06):1321–1328
- 14 Drago L, Bortolin M, Vassena C, Taschieri S, Del Fabbro M. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. *BMC Microbiol* 2013;13:47
- 15 Moussa M, Lajeunesse D, Hilal G, et al. Platelet rich plasma (PRP) induces chondroprotection via increasing autophagy, anti-inflammatory markers, and decreasing apoptosis in human osteoarthritic cartilage. *Exp Cell Res* 2017;352(01):146–156
- 16 Sánchez M, Anitua E, Azofra J, Andía I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. *Am J Sports Med* 2007;35(02):245–251
- 17 Hammond JW, Hinton RY, Curl LA, Muriel JM, Lovering RM. Use of autologous platelet-rich plasma to treat muscle strain injuries. *Am J Sports Med* 2009;37(06):1135–1142
- 18 Joshi SM, Mastrangelo AN, Magarian EM, Fleming BC, Murray MM. Collagen-platelet composite enhances biomechanical and histologic healing of the porcine anterior cruciate ligament. *Am J Sports Med* 2009;37(12):2401–2410
- 19 Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. *Am J Sports Med* 2013;41(02):356–364
- 20 Charoussat C, Zaoui A, Bellaiche L, Bouyer B. Are multiple platelet-rich plasma injections useful for treatment of chronic patellar tendinopathy in athletes? A prospective study. *Am J Sports Med* 2014;42(04):906–911
- 21 Spartalis E, Athanasiou A, Spartalis M, Moris D, Papalampros A, Nikiteas N. Platelet-rich plasma and peripheral nerve regeneration: a potential contraindication to its use after tumor excision. *Expert Opin Biol Ther* 2017;17(08):1045–1046
- 22 Obata S, Akeda K, Imanishi T, et al. Effect of autologous platelet-rich plasma-releasate on intervertebral disc degeneration in the rabbit anular puncture model: a preclinical study. *Arthritis Res Ther* 2012;14(06):R241
- 23 Nagae M, Ikeda T, Mikami Y, et al. Intervertebral disc regeneration using platelet-rich plasma and biodegradable gelatin hydrogel microspheres. *Tissue Eng* 2007;13(01):147–158
- 24 Kon E, Buda R, Filardo G, et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. *Knee Surg Sports Traumatol Arthrosc* 2010;18(04):472–479
- 25 Singla V, Batra YK, Bharti N, Goni VG, Marwaha N. Steroid vs. platelet-rich plasma in ultrasound-guided sacroiliac joint injection for chronic low back pain. *Pain Pract* 2017;17(06):782–791
- 26 Levi D, Horn S, Tyszko S, Levin J, Hecht-Leavitt C, Walko E. Intradiscal platelet-rich plasma injection for chronic discogenic low back pain: preliminary results from a prospective trial. *Pain Med* 2016;17(06):1010–1022
- 27 Tuakli-Wosornu YA, Terry A, Boachie-Adjei K, et al. Lumbar intradiscal platelet-rich plasma (PRP) injections: a prospective, double-blind, randomized controlled study. *PM R* 2016;8(01):1–10; quiz 10 quiz
- 28 Wu J, Zhou J, Liu C, et al. A prospective study comparing platelet-rich plasma and local anesthetic (LA)/corticosteroid in intra-articular injection for the treatment of lumbar facet joint syndrome. *Pain Pract* 2017;17(07):914–924
- 29 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535
- 30 Higgins JPT, Thomas J, Chandler J, et al, eds. *Cochrane Handbook for Systematic Reviews of Interventions* version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011. Available from: [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook)
- 31 Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17(01):1–12
- 32 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Ann Intern Med* 2001;135(11):982–989
- 33 Kabiri A, Esfandiari E, Esmaeili A, Hashemibeni B, Pourazar A, Mardani M. Platelet-rich plasma application in chondrogenesis. *Adv Biomed Res* 2014;3:138
- 34 Yadav R, Kothari SY, Borah D. Comparison of local injection of platelet rich plasma and corticosteroids in the treatment of lateral epicondylitis of humerus. *J Clin Diagn Res* 2015;9(07):RC05–RC07
- 35 Duan X, Sandell IJ, Chinzei N, et al. Therapeutic efficacy of intra-articular hyaluronan derivative and platelet-rich plasma in mice following axial tibial loading. *PLoS One* 2017;12(04):e0175682
- 36 Wei LC, Lei GH, Sheng PY, et al. Efficacy of platelet-rich plasma combined with allograft bone in the management of displaced intra-articular calcaneal fractures: a prospective cohort study. *J Orthop Res* 2012;30(10):1570–1576
- 37 Bendinelli P, Matteucci E, Dogliotti G, et al. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF. *J Cell Physiol* 2010;225(03):757–766
- 38 Mazzocca AD, McCarthy MB, Intravia J, et al. An in vitro evaluation of the anti-inflammatory effects of platelet-rich plasma, ketorolac, and methylprednisolone. *Arthroscopy* 2013;29(04):675–683
- 39 Masuki H, Okudera T, Watanebe T, et al. Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). *Int J Implant Dent* 2016;2(01):19

- 40 Meheux CJ, McCulloch PC, Lintner DM, Varner KE, Harris JD. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. *Arthroscopy* 2016;32(03):495–505
- 41 Fukawa T, Yamaguchi S, Akatsu Y, Yamamoto Y, Akagi R, Sasho T. Safety and efficacy of intra-articular injection of platelet-rich plasma in patients with ankle osteoarthritis. *Foot Ankle Int* 2017;38(06):596–604
- 42 Battaglia M, Guaraldi F, Vannini F, et al. Efficacy of ultrasound-guided intra-articular injections of platelet-rich plasma versus hyaluronic acid for hip osteoarthritis. *Orthopedics* 2013;36(12):e1501–e1508